> Details

Stephan, Carsten; Jung, Klaus; Cammann, Henning; Vogel, Birgit; Brux, Brigitte; Kristiansen, Glen; Rudolph, Birgit; Hauptmann, Steffen; Lein, Michael; Schnorr, Dietmar; Sinha, Pranav; Loening, Stefan A.

An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation
  • Contributor: Stephan, Carsten; Jung, Klaus; Cammann, Henning; Vogel, Birgit; Brux, Brigitte; Kristiansen, Glen; Rudolph, Birgit; Hauptmann, Steffen; Lein, Michael; Schnorr, Dietmar; Sinha, Pranav; Loening, Stefan A.
  • imprint: Wiley, 2002
  • Published in: International Journal of Cancer
  • Language: English
  • DOI: 10.1002/ijc.10370
  • ISSN: 0020-7136; 1097-0215
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Our study was performed to evaluate the diagnostic usefulness of %fPSA alone and combined with an ANN at different PSA concentration ranges, including the low range 2–4 ng/ml, to improve the risk assessment of prostate cancer. A total of 928 men with prostate cancer and BPH without any pretreatment of the prostate in the PSA range 2–20 ng/ml were enrolled in the study between 1996 and 2001. An ANN with input data of PSA, %fPSA, patient's age, prostate volume and DRE status was developed to calculate the individual's risk before performing a prostate biopsy within the different PSA ranges 2–4, 4.1–10 and 10.1–20 ng/ml. ROC analysis and cut‐off calculations were used to estimate the diagnostic improvement of %fPSA and ANN in comparison to PSA. At the 90% sensitivity level, %fPSA and ANN performed better than PSA in all ranges, enhancing the specificity by 15–28% and 32–44%, respectively. For the low PSA range 2–4 ng/mL, we recommend a first‐time biopsy at an ANN specificity level of 90%. For PSA 4–10 ng/mL, we recommend a first‐time biopsy based on the ANN at the 90% sensitivity level. Use of an ANN enhances the %fPSA performance to further reduce the number of unnecessary biopsies within the PSA range 2–10 ng/ml. © 2002 Wiley‐Liss, Inc.</jats:p>
  • Access State: Open Access